Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V, Cassibba S, Cesareo R, Chiodini I, Francucci C Maria, Gianotti L, Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A, Vignali E, Rochira V, Zini M
Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, P.le S.M. della Misericordia, 15, 33100, Udine, Italy.
Endocrinology Service, Galeazzi Institute IRCCS, Milan, Italy.
J Endocrinol Invest. 2016 Jul;39(7):807-34. doi: 10.1007/s40618-016-0434-8. Epub 2016 Mar 11.
Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.
骨质疏松症的治疗旨在预防脆性骨折，并稳定或增加骨矿物质密度。有几种疗效和安全性不同的药物可供使用。应制定长期治疗策略，并根据个体特定部位的骨折风险以及在骨折风险最高时（即晚年）给予最大保护的需求来选择初始治疗方法。目前的共识聚焦于绝经后骨质疏松症的治疗策略，同时考虑到为此目的可用的所有药物。还对有关前列腺癌雄激素剥夺疗法和乳腺癌芳香化酶抑制剂所致继发性骨质疏松症治疗的文献进行了简要回顾。在内分泌环境中也经常见到绝经前患有骨质疏松症的女性和男性。最后，特别关注了治疗方案的调整及其持续时间。
